Literature DB >> 21801636

Poliomyelitis outbreak, Pointe-Noire, Republic of the Congo, September 2010-February 2011.

Arnaud Le Menach1, Augusto E Llosa, Isabelle Mouniaman-Nara, Felix Kouassi, Joseph Ngala, Naomi Boxall, Klaudia Porten, Rebecca F Grais.   

Abstract

On November 4, 2010, the Republic of the Congo declared a poliomyelitis outbreak. A cross-sectional survey in Pointe-Noire showed poor sanitary conditions and low vaccination coverage (55.5%), particularly among young adults. Supplementary vaccination should focus on older age groups in countries with evidence of immunity gaps.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801636      PMCID: PMC3381570          DOI: 10.3201/eid1708.110195

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


On November 4, 2010, the Ministry of Health of the Republic of the Congo officially declared a poliomyelitis outbreak centered in Pointe-Noire following the laboratory identification of poliovirus type 1 in a patient with acute flaccid paralysis (AFP) (,). A provisional total of 554 AFP case-patients that included a high proportion (68%) of male patients was identified nationally, with paralysis onset from September 20, 2010, through February 27, 2011 (). During this same period, 451 cases (81.4%), which included 184 deaths, were reported in Pointe-Noire. Most cases were found in the young adult population (57.4% in patients 15–24 years of age), which had a higher case-fatality ratio (CFR) of 40.8% compared with the general population of the country (). In most developing countries, prevention and control of poliomyelitis relies on oral polio vaccine (OPV). Routine vaccination focuses on infants <11 months of age with trivalent OPV, and supplementary immunization activities (SIAs) provide additional opportunities for vaccination for children <5 years of age (,). In response to the epidemic, the Ministry of Health, in collaboration with the World Health Organization, launched 4 rounds of national SIAs that used monovalent type 1 and bivalent types 1 and 3 OPV during November 12–16, 2010, December 3–7, 2010, January 11–15, 2011, and February 22–26, 2011 (). To assess risk factors for infection and estimate vaccination coverage, Epicentre and Médecins Sans Frontières implemented a cross-sectional survey in 1 affected neighborhood of Pointe-Noire.

The Study

This survey was a single-community rapid assessment of epidemiologic conditions potentially contributing to the outbreak, including vaccination coverage. The survey was done in Mbota, a neighborhood composed of 4 sectors, comprising 9.5% of the city population. This neighborhood was selected from Loandjili district (Figure 1) on the basis of local expert consultation to ensure socioeconomic diversity and representativeness. To estimate vaccination coverage of 80% among children with 5% precision at a 95% confidence level, we aimed to sample at least 246 households. We assumed each household had on average 1 child <5 years of age. We also assumed 5 persons per household on average, which corresponds to ≈1,230 persons overall. Households were selected in each sector of the neighborhood. From a starting point on the border of the sector, interviews focused on every fifth household, following a predefined direction toward the center of the sector, subsequently covering the entire neighborhood. Data were collected through face-to-face interviews December 9–10, 2010, by using a structured questionnaire. The questions included household demographics, water supply, and sanitary conditions. In addition, information for each person in the household was collected about vaccination history (routine and SIAs), any previous illness, and access to health care during the past 3 months. Vaccination coverage was estimated on the basis of reported personal history or documentary evidence of vaccination: a fingernail marked with ink indicating vaccination during SIAs or a vaccination card indicating routine vaccination.
Figure 1

Pointe-Noire, Republic of the Congo, representing the 4 districts, Lumuba, MvouMvou, Tie-Tie, and Loandjili. The gray scale represents the cumulative acute flaccid paralysis (AFP) rate per 100,000 inhabitants September 2010–February 2011. Black area represents the 4 sectors of Mbota where the cross-sectional survey took place. The last census provided by local health authorities occurred in 2007, with a growth rate applied to estimate the 2010 official population size in Pointe-Noire, aggregated by gender and age. We used a 2005 population survey to disaggregate population figures by gender and 5-year age groups and calculate specific acute flaccid paralysis rate. DRC, Democratic Republic of the Congo.

Pointe-Noire, Republic of the Congo, representing the 4 districts, Lumuba, MvouMvou, Tie-Tie, and Loandjili. The gray scale represents the cumulative acute flaccid paralysis (AFP) rate per 100,000 inhabitants September 2010–February 2011. Black area represents the 4 sectors of Mbota where the cross-sectional survey took place. The last census provided by local health authorities occurred in 2007, with a growth rate applied to estimate the 2010 official population size in Pointe-Noire, aggregated by gender and age. We used a 2005 population survey to disaggregate population figures by gender and 5-year age groups and calculate specific acute flaccid paralysis rate. DRC, Democratic Republic of the Congo. Data were eventually collected from 1,849 persons in 317 households of Mbota with all ages and both genders represented. Following the 2 first rounds of SIAs, most surveyed persons (1,812 [98%], 95% confidence interval [CI] 97.3%–98.6%) reported having been vaccinated with monovalent OPV and 1,769 (95.7%, 95% CI 94.7%–96.6%) received 2 doses in November and December 2010. Among vaccinated persons, 627 (33.9%, 95% CI 31.7%–36.1%) had fingernails marked with ink; the rest were absent during the interview or ink had already worn off. There were no significant differences in SIA vaccine coverage by gender or age. Routine vaccination coverage was estimated as 55.5% (95% CI 53.3%–57.8%) among the surveyed persons (Table 1). Among reported vaccinated persons, 21.3% (95% CI 18.8%–23.8%) showed their vaccination card, and among those, 78.7% (95% CI 73.1%–84.4%) were vaccinated >3 times. Routine vaccination coverage did not vary significantly by gender but decreased with age (p <0.0001). For persons younger than 5 years, it was 87.5% (95% CI 83.6%–91.4%) and <52% for anyone >15 years of age. In the most affected age groups, 15–19 and 20–24 years, vaccination coverage was estimated to be respectively 49.3% (95% CI 42.4%–56.1%) and 46.2% (95% CI 39.3%–53.1%) (Figure 2). By comparison, administrative vaccination coverage varied since 1986 between a reported 21% in 1997 and 112% in 2009 (Table 2).
Table 1

Persons vaccinated against poliomyelitis (routine vaccination), by age and gender, Mbota, Pointe-Noire, Republic of the Congo, December 2010

Age, y, and genderNo. (%) persons*
Total no. persons
Vaccinated, cardVaccinated, recallTotal vaccinatedNonvaccinatedUnknown
<5
M43 (35.5)67 (55.4)110 (90.9)5 (4.1)6 (5)121
F54 (36.2)72 (48.3)126 (84.5)9 (6)14 (9.4)149
Total
97 (35.9)
139 (51.5)
236 (87.4)
14 (5.2)
20 (7.4)
270
5–9
M26 (25.5)53 (52)79 (77.5)10 (9.8)13 (12.8)102
F23 (20.9)66 (60)89 (80.9)7 (6.4)14 (12.7)110
Total
49 (23.1)
119 (56.1)
168 (79.2)
17 (8)
27 (12.7)
212
10–14
M7(7.2)62 (63.9)69 (71.1)9 (9.3)19 (19.6)97
F16 (16)51 (51)67 (67)7 (7)26 (26)100
Total
23 (11.7)
113 (57.4)
136 (69.1)
16 (8.1)
45 (22.8)
197
15–19
M4 (4.4)39 (42.4)43 (46.8)9 (9.8)40 (43.5)92
F8 (7.3)49 (45)57 (52.3)12 (11)40 (36.7)109
Total
12 (6)
88 (43.8)
100 (49.8)
21 (10.4)
80 (39.8)
201
20–24
M2 (3)25 (37.3)27 (40.3)7 (10.5)33 (49.3)67
F4 (3.2)61 (48)65 (51.2)14 (11)48 (37.8)127
Total
6 (3.1)
86 (44.3)
92 (47.4)
21 (10.8)
81 (41.8)
194
25–29
M2 (2.3)37 (43)39 (45.3)12 (14)35 (40.7)86
F11 (10.4)50 (47.2)61 (57.6)15 (14.2)30 (28.3)106
Total
13 (6.6)
87 (45.3)
100 (51.9)
27 (14.1)
65 (33.9)
192
>29
M4 (1.5)80 (29.2)84 (30.7)33 (12)157 (57.3)274
F11 (4.2)84 (32.3)95 (36.5)30 (11.5)135 (51.9)260
Total
15 (2.8)
164 (30.7)
179 (33.5)
63 (11.8)
292 (54.7)
534
Totals
M88 (10.5)363 (43.3)451 (53.8)85 (10.1)303 (36.1)839
F127 (13.2)433 (45.1)560 (58.3)94 (9.8)307 (32)961
Total215 (11.9)796 (44.2)1,011 (56.1)179 (10)610 (33.9)1,800

*Card, vaccination documented by card; recall, person remembers received vaccination; total, card + recall.

Figure 2

Routine vaccination coverage and acute flaccid paralysis (AFP) rate by birth cohort. Gray bars represents the vaccination coverage according to the survey implemented in Mbota, Pointe-Noire, Republic of the Congo, in December 2010. Error bars represent the 95% confidence interval). Black squares represent AFP rate per 100,000 inhabitants for each of the designated birth cohorts.

Table 2

Cumulative age-specific AFP rate and vaccination coverage from administrative data and a cross-sectional survey conducted in December 2010, by age group, Mbota, Pointe-Noire, Republic of the Congo*

Age group, y
AFP rate/100,000 persons (95% CI)
Survey vaccination coverage, % (95% CI)
Administrative vaccination coverage, %
5-y average administrative vaccination coverage, %
>2923.1 (16.9–29.3)33.3 (29.4–37.3)
25–2980.5 (59.2–101.8)52.6 (45.5–59.6)
20–24151.1 (124.3–177.9)46.2 (39.3–53.2)41.7–79.067.0
15–19136.5 (112.4–160.6)49.3 (42.4–56.2)47–77†60.5†
10–1431.9 (20.7–43.2)69.0 (62.6–75.5)21–75†36.7†
5–916.3 (8.1–24.6)79.3 (73.7–84.7)38–6753.1
0–444.5 (32.2–56.8)87.5 (83.6–91.4)81–11293.9

*AFP, acute flaccid paralysis; CI, confidence interval.
†Administrative vaccination coverage provided by health authorities at the country level 1986–2000, at the regional level 2001–2006, and at the city level 2007–2009. Vaccination coverage was partially incomplete for 1992–2000 because of civil conflict. Thus, values for 1994, 1998, and 2000 consisted of interpolated values from years for which data are available.

*Card, vaccination documented by card; recall, person remembers received vaccination; total, card + recall. Routine vaccination coverage and acute flaccid paralysis (AFP) rate by birth cohort. Gray bars represents the vaccination coverage according to the survey implemented in Mbota, Pointe-Noire, Republic of the Congo, in December 2010. Error bars represent the 95% confidence interval). Black squares represent AFP rate per 100,000 inhabitants for each of the designated birth cohorts. *AFP, acute flaccid paralysis; CI, confidence interval.
†Administrative vaccination coverage provided by health authorities at the country level 1986–2000, at the regional level 2001–2006, and at the city level 2007–2009. Vaccination coverage was partially incomplete for 1992–2000 because of civil conflict. Thus, values for 1994, 1998, and 2000 consisted of interpolated values from years for which data are available. The number of persons per bedroom, an indicator of crowding, ranged between 1 and 9, and there were >4 persons per bedroom for 12.1% (95% CI 8.4%–15.7%) of all households with no statistical differences among sectors. Tap water either from a neighbor’s house (41.9%, 95% CI 35.9%–47.8%) or within the house (30.7%, 95% CI 25.2%–36.3%) was the primary potable water source recorded. Wells were also common (23.3%, 95% CI 18.3%–28.4%). When the primary source of potable water was unavailable, wells were the most frequently mentioned alternative source (37.8%, 95% CI 32.0%–43.6%). Most households reported use of a latrine shared with neighbors (57.4%, 95% CI 51.8%–63.1%) or within their house (31.4%, 95% CI 26.1%–36.7%). Few surveyed persons (16.1%, 95% CI 14.4%–17.7%) reported illness during the recall period, but if sick, 73.3% (95% CI 67.4%–79.2%) they sought health care, which suggests little underreporting of AFP cases.

Conclusions

The cross-sectional survey confirmed administrative estimates of low routine vaccination decreasing with age. Specifically, in the surveyed young adult population (15–29 years of age) it varied between a reported 46.2% and 52.6%. According to administrative data, the reported vaccination coverage varies between 41.7% and 79% in young adults between 15 and 24 years of age. Civil conflicts spanning the 1990s have potentially undermined vaccination efforts, especially affecting those currently 10–20 years of age. A further method of protection for a person is past exposure to wildtype strains. To our knowledge, no polio transmission had been reported in Pointe-Noire since the last outbreak in the city in 1969 (). Low vaccination coverage and no previous exposure to wild virus likely led to an accumulation of susceptible persons. Once introduced, the disease spread quickly through this highly susceptible, undervaccinated, and underexposed young adult population, with disease spread facilitated by frequent flooding and poor to medium household sanitation conditions, i.e., crowding sleeping areas, shared latrines between households, and common sources for water consumption. Poliovirus infections lead to clinical disease more frequently in older age groups (), which partially explains the observed shift of AFP cases toward young adult populations. Moreover, children were better protected with higher vaccination coverage. Death is more frequent when infection occurs in older age groups (,), which explains part of the high observed CFR. Clinical manifestations of poliovirus infections are more common in boys and men than in girls and women (), as observed, and even though males and females share similar vaccination coverage, women in the young adult age groups may have additionally benefitted from exposure to excreted OPV while caring for the young (). As seen in the Republic of the Congo, or previously in Namibia (), Cape-Verde (), any country with no recent wild-type polio transmission and a similarly low level of vaccination coverage may face similar outbreaks characterized by a large proportion of cases in older age groups and a high CFR (). Avoiding outbreaks will rely on ensuring vaccination of the at-risk population. Routine vaccination activities should be reinforced by SIAs punctually focusing on older age groups (especially among persons 15–35 years of age) when evidence of immunity gaps are documented by serologic surveys or low historical vaccination coverage data. Lessons from the epidemic should benefit health authorities in better prevention and response to further outbreaks on the road to eradication.
  11 in total

1.  Outbreak of poliomyelitis, Cape Verde.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2000-12-08

2.  Influence of age and sex on susceptibility and clinical manifestations in poliomyelitis.

Authors:  L WEINSTEIN
Journal:  N Engl J Med       Date:  1957-07-11       Impact factor: 91.245

3.  Infectious disease. Polio outbreak breaks the rules.

Authors:  Leslie Roberts
Journal:  Science       Date:  2010-12-24       Impact factor: 47.728

4.  Seven die in polio outbreak in Namibia.

Authors:  Pat Sidley
Journal:  BMJ       Date:  2006-06-17

5.  A comparison of the clinical features of poliomyelitis in adults and in children.

Authors:  L WEINSTEIN; A SHELOKOV; R SELTSER; G D WINCHELL
Journal:  N Engl J Med       Date:  1952-02-21       Impact factor: 91.245

6.  [Poliomyelitis epidemic at Pointe-Noire].

Authors:  L Heraut; E Rousseau; P Aubry
Journal:  Med Trop (Mars)       Date:  1969 May-Jun

7.  A continuing surveillance of enterovirus infection in healthy children in six United States cities. II. Surveillance enterovirus isolates 1960-1963 and comparison with enterovirus isolates from cases of acute central nervous system disease.

Authors:  J E Froeschle; P M Feorino; H M Gelfand
Journal:  Am J Epidemiol       Date:  1966-05       Impact factor: 4.897

8.  Poliomyelitis outbreak--Republic of the Congo, September 2010-February 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-03-18       Impact factor: 17.586

9.  Type 1 wild poliovirus and putative enterovirus 109 in an outbreak of acute flaccid paralysis in Congo, October-November 2010.

Authors:  G Grard; J F Drexler; S Lekana-Douki; M Caron; A Lukashev; D Nkoghe; J P Gonzalez; C Drosten; E Leroy
Journal:  Euro Surveill       Date:  2010-11-25

Review 10.  From emergence to eradication: the epidemiology of poliomyelitis deconstructed.

Authors:  Neal Nathanson; Olen M Kew
Journal:  Am J Epidemiol       Date:  2010-10-26       Impact factor: 4.897

View more
  13 in total

1.  Reply to 'apropos "seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China"'.

Authors:  Haibo Wang; Hui Cui; Zhengrong Ding; Pian Ba; Shuangli Zhu; Ning Wen; Lixin Hao; Jing Ning; Jie Zhang; De Yang; Wenbo Xu; Yong Zhang; Chunxiang Fan; Wenzhou Yu; Xiaofeng Liang; Huiming Luo
Journal:  Clin Vaccine Immunol       Date:  2013-10

2.  An outbreak of wild poliovirus in the Republic of Congo, 2010-2011.

Authors:  Minal K Patel; Mandy Kader Konde; Boris Hermann Didi-Ngossaki; Edouard Ndinga; Riziki Yogolelo; Mbaye Salla; Keith Shaba; Johannes Everts; Gregory L Armstrong; Danni Daniels; Cara Burns; Steve Wassilak; Mark Pallansch; Katrina Kretsinger
Journal:  Clin Infect Dis       Date:  2012-08-21       Impact factor: 9.079

3.  Seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China.

Authors:  HaiBo Wang; Hui Cui; ZhenGrong Ding; Pian Ba; ShuangLi Zhu; Ning Wen; LiXin Hao; Jing Ning; Jie Zhang; De Yang; WenBo Xu; Yong Zhang; ChunXiang Fan; WenZhou Yu; XiaoFeng Liang; HuiMing Luo
Journal:  Clin Vaccine Immunol       Date:  2013-05-15

4.  Adverse events following immunization with oral poliovirus in Kinshasa, Democratic Republic of Congo: preliminary results.

Authors:  Didier Nzolo; Michel Ntetani Aloni; Thérèse Mpiempie Ngamasata; Bibiche Mvete Luemba; Sandrine Bazundama Marfeza; Mathilde Bothale Ekila; Célestin Ndosimao Nsibu; Narcisse Lutete Tona
Journal:  Pathog Glob Health       Date:  2013-10       Impact factor: 2.894

5.  Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010.

Authors:  Jan Felix Drexler; Gilda Grard; Alexander N Lukashev; Liubov I Kozlovskaya; Sindy Böttcher; Gökhan Uslu; Johan Reimerink; Anatoly P Gmyl; Raphaël Taty-Taty; Sonia Etenna Lekana-Douki; Dieudonné Nkoghe; Anna M Eis-Hübinger; Sabine Diedrich; Marion Koopmans; Eric M Leroy; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

6.  Assessment of attitudes towards adverse events following immunization with oral poliovirus vaccine: a pilot study among high school students of Kinshasa, the Democratic Republic of Congo.

Authors:  Léon Kinuani; Didier Bomene Nzolo; Michel Ntetani Aloni; Pavel Makolo; Nsengi Ntamabyaliro; Yves Lula Ntamba; Crispin Kazadi; Michel Nyembwe; Mathilde Bothale Ekila; Gauthier Kahunu Mesia
Journal:  Pathog Glob Health       Date:  2014-09-19       Impact factor: 2.894

7.  The role of older children and adults in wild poliovirus transmission.

Authors:  Isobel M Blake; Rebecca Martin; Ajay Goel; Nino Khetsuriani; Johannes Everts; Christopher Wolff; Steven Wassilak; R Bruce Aylward; Nicholas C Grassly
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

8.  [Investigation and response to an outbreak of wild poliovirus in Kinshasa].

Authors:  Muriel Nzazi Nsambu; Léodegal Bazira; Tiekoura Coulibaly; Albert Mbule; Michèle Dramaix Wilmet; Joris Losimba Likwela
Journal:  Pan Afr Med J       Date:  2013-05-31

9.  Enhanced surveillance of acute flaccid paralysis following importation of wild poliovirus in Xinjiang Uygur Autonomous Region, China.

Authors:  Ning Wen; Chun-Xiang Fan; Jian-Ping Fu; Jing Ning; Yi-Xin Ji; Hui-Ming Luo; Hua-Qing Wang; Shuang-Li Zhu; Wen-Zhou Yu; Hai-Bo Wang; Hui Zhu; Fu-Qiang Cui; De-Xin Li; Shi-Wen Wang; Wen-Bo Xu; Li-Xin Hao; Ling-Sheng Cao; Li Luo; Lu Han; Lei Cao; Wei Xia; Xin-Qi Wang; Kathleen H Reilly; Fuerhati Wushouer; Sha-Sha Mi; Wei-Zhong Yang; Li Li
Journal:  BMC Infect Dis       Date:  2014-02-27       Impact factor: 3.090

10.  Sero-survey of polio antibodies during wild poliovirus outbreak in southern Xinjiang Uygur Autonomous Region, China.

Authors:  Hai-Bo Wang; Shuang-Li Zhu; Jing-Shan Zheng; Ai-Li Gou; Hui Cui; Yong Zhang; Gui-Jun Ning; Chun-Xiang Fan; Yuan-Sheng Chen; Ke-Li Li; Ping Yuan; Chao Ma; Jing Ma; Hui Zheng; Xin-Chun Fan; Xin-Lan Li; Hai-Shu Tang; Xiao-Lei Li; Fan Zhang; Dong-Mei Yan; Dong-Yan Wang; Zhi-Qiang Cui; Li-Ping Ren; Hui Zhu; Hui-Ling Wang; Xiao-Hong Jiang; Hong-Qiu An; Yang Liu; Jing Li; Wen-Bo Xu; Ning Wen; Ai-Qiang Xu; Hui-Ming Luo
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.